Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

CREST study data published in The New England Journal of Medicine

CREST study data published in The New England Journal of Medicine

Abbott's TREK Coronary Dilatation Catheter receives European approval

Abbott's TREK Coronary Dilatation Catheter receives European approval

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

St. Jude Medical to evaluate cost-effectiveness of FFR for multivessel coronary artery disease

St. Jude Medical to evaluate cost-effectiveness of FFR for multivessel coronary artery disease

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

Bayer's Adalat XL product and Mylan's nifedipine extended release 60 mg not bioequivalent: Study

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Blood biomarker underscores role of inflammation in vascular disease

Blood biomarker underscores role of inflammation in vascular disease

Significant proportion of men with ED exhibit early signs of CAD: Review

Significant proportion of men with ED exhibit early signs of CAD: Review

Study reveals association between depression and coronary spasm

Study reveals association between depression and coronary spasm

Apnex HGNS System shows promising results in people suffering from OSA

Apnex HGNS System shows promising results in people suffering from OSA

SPIROCOR's RSR non-invasively measures presence of significant coronary artery disease

SPIROCOR's RSR non-invasively measures presence of significant coronary artery disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.